Given the close link between impaired insulin actions and HF, the correction of insulin resistance and hyperinsulinemia induced by SGLT2 inhibition likely contributed to the clinical benefits observed in those CVOTs [21]. The gene discussed is SLC5A2; the disease is Hyperinsulinemia.